Purpose

A single arm, pilot study in which all eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • • Adults aged 18 years of age and older - Dermatologist confirmed diagnosis of psoriasis - Current depression symptoms, defined as a PHQ-9 score of 5 or greater - Current psoriasis symptoms, defined as a scaled score of "mild" on any of the Skindex-16 subscales - Participants must be proficient in English and have access to an Android or iOS smartphone

Exclusion Criteria

  • Previous participation in CBT for depression - Current participation in any type of psychotherapy - Those on psychotropic medications must be taking a stable dose for 2 months prior to enrollment and be willing to remain at a stable dose during the 8-week study - Current elevated suicide risk (see Section 5.3 for details) - Individuals who are incarcerated or compulsory detained - Any uncontrolled or poorly controlled chronic medical condition that may interfere with an individual's ability to participate in the clinical trial

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Other
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Other
Coach-guided smartphone delivered CBT program
All eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.
  • Other: Coach-guided smartphone delivered CBT program.
    All eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.

Recruiting Locations

More Details

Status
Recruiting
Sponsor
Brigham and Women's Hospital

Study Contact

Liset Chacin
617-264-5926
lchacin@bwh.harvard.edu

Detailed Description

1. To demonstrate the feasibility and acceptability of coach-guided, smartphone-delivered CBT for depression among adults with psoriasis 2. To demonstrate the preliminary efficacy of coach-guided, smartphone-delivered CBT on the symptoms of depression and psoriasis Primary endpoints - Percentage of participants who engage with at least 6/8 (75%) modules - Median Client Satisfaction Questionnaire-8 score at week 8 - Change from baseline in PHQ-9 at week 8 Secondary Endpoints - Rate of participant dropout - App acceptability to participants, as measured by the uMARS - Change from baseline in Skindex-16 at week 8 - Change from baseline in PSI at week 8 - Change from baseline in AAI at week 8 - Frequency & severity of related adverse events - The patient perspective on the feasibility and acceptability (qualitative) Analysis Plan Investigators will assess the feasibility of smartphone-based CBT by reporting the proportion of participants who engaged with at least 75% of the treatment modules and assess patient acceptability with descriptive statistics summarizing the Client Satisfaction Questionnaire scores. Paired t-tests will be used to examine the differences in the pre- and post- treatment PHQ-9 scores, in all patients who complete the baseline study visit. Additionally, secondary outcomes (dropout rates, patient feedback from the Mobile Application Rating Scale, Skindex-16, Psoriasis Symptom Inventory, Appearance Anxiety Inventory) will be reported descriptively. Post-treatment interviews will be transcribed, edited for clarity, coded to identify themes and summarized.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.